{"id":"pantoprazole-high-dose","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Headache"},{"rate":"10-12","effect":"Diarrhea"},{"rate":"7-9","effect":"Nausea"},{"rate":"5-8","effect":"Abdominal pain"},{"rate":"4-6","effect":"Constipation"},{"rate":null,"effect":"Hypomagnesemia (with long-term use)"},{"rate":null,"effect":"Vitamin B12 deficiency (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pantoprazole binds to and inactivates the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, preventing the final step of gastric acid production. This results in sustained reduction of both basal and stimulated gastric acid secretion. High-dose formulations are used to manage severe acid-related conditions and are particularly effective in treating gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome.","oneSentence":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:25:36.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Severe acid-related conditions requiring high-dose therapy"}]},"trialDetails":[{"nctId":"NCT04394663","phase":"NA","title":"High Dose Oral Omeprazole in High Risk UGIB","status":"RECRUITING","sponsor":"King Chulalongkorn Memorial Hospital","startDate":"2020-10-01","conditions":"GI Bleeding","enrollment":128},{"nctId":"NCT07084753","phase":"NA","title":"Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy","status":"NOT_YET_RECRUITING","sponsor":"IVO JURISIC","startDate":"2025-07-30","conditions":"Obese Patients, Bariatric Surgical Pain, Bariatric Surgery (Sleeve Gastrectomy )","enrollment":36},{"nctId":"NCT06348420","phase":"NA","title":"Anti-reflux Mucosal Valvuloplasty Versus PPIs for GERD Treatment","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-09-10","conditions":"Gastroesophageal Reflux Disease","enrollment":74},{"nctId":"NCT00825630","phase":"PHASE4","title":"13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2008-11","conditions":"Helicobacter Pylori Infection","enrollment":123},{"nctId":"NCT02197039","phase":"","title":"The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Hemorrhage","enrollment":316},{"nctId":"NCT02167633","phase":"NA","title":"Stereotactic Radiosurgery in Metastatic Spinal Cord Compression","status":"TERMINATED","sponsor":"Rigshospitalet, Denmark","startDate":"2014-07","conditions":"Spinal Cord Compression, Neoplasm Metastasis","enrollment":10},{"nctId":"NCT03814421","phase":"NA","title":"Efficacy of Low Dose Intravenous Proton Pump Inhibitor for Peptic Ulcer Bleeding","status":"UNKNOWN","sponsor":"Samsung Changwon Hospital","startDate":"2016-04-15","conditions":"Peptic Ulcer Hemorrhage, Peptic Ulcer, Acute With Hemorrhage, Peptic Ulcer","enrollment":200},{"nctId":"NCT01848457","phase":"PHASE2","title":"Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2013-04","conditions":"Osteosarcoma, Nephrotoxicity, Ototoxicity","enrollment":13},{"nctId":"NCT04217512","phase":"PHASE3","title":"Pantoprazole in Cisplatin Nephrotoxicity","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2019-05-01","conditions":"Oncology","enrollment":60},{"nctId":"NCT00744419","phase":"PHASE1","title":"Intravenous (IV) Pantoprazole for Gastroesophageal Reflux Disease (GERD) in Neonates and Infants","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2009-05","conditions":"Gastroesophageal Reflux","enrollment":24},{"nctId":"NCT01447498","phase":"NA","title":"Systematic Screening for Risk-factors for Ulcer Bleeding Before Anti-thrombotic Treatment","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2011-04","conditions":"Coronary Occlusion/Thrombosis, Peptic Ulcer Hemorrhage","enrollment":2024},{"nctId":"NCT00881413","phase":"PHASE4","title":"Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding","status":"WITHDRAWN","sponsor":"Lotung Poh-Ai Hospital","startDate":"","conditions":"Peptic Ulcer","enrollment":""},{"nctId":"NCT02214433","phase":"PHASE1","title":"A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2014-08","conditions":"Bacterial Infections","enrollment":70},{"nctId":"NCT02170766","phase":"PHASE1","title":"Bioavailability of BIBR 953 ZW in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT02170740","phase":"PHASE1","title":"Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT01179724","phase":"NA","title":"Comparison of Proton Pump Inhibitor and H2 Receptor Blocker on Prevention of Bleeding From Iatrogenic Ulcer After Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2009-07","conditions":"Delayed Bleeding","enrollment":206},{"nctId":"NCT00300755","phase":"PHASE3","title":"Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-05","conditions":"Gastroesophageal Reflux","enrollment":60},{"nctId":"NCT00362609","phase":"PHASE3","title":"Study Evaluating Pantoprazole in Neonates and Preterm Infants With GERD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-07","conditions":"Gastroesophageal Reflux","enrollment":59},{"nctId":"NCT00259012","phase":"PHASE3","title":"Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-11","conditions":"Gastroesophageal Reflux","enrollment":67},{"nctId":"NCT00868296","phase":"PHASE3","title":"Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Gastroesophageal Reflux","enrollment":58},{"nctId":"NCT00709046","phase":"NA","title":"High Dose Versus Standard Dose Proton Pump Inhibitor (PPI) in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Treatment","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Endoscopy, Peptic Ulcer, Bleeding","enrollment":150},{"nctId":"NCT00374101","phase":"PHASE3","title":"High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding","status":"COMPLETED","sponsor":"Casa Sollievo della Sofferenza IRCCS","startDate":"2005-01","conditions":"Peptic Ulcers, Upper Gastrointestinal Bleeding","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":103,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["zurcal, Controloc"],"phase":"phase_3","status":"active","brandName":"Pantoprazole high dose","genericName":"Pantoprazole high dose","companyName":"Sherief Abd-Elsalam","companyId":"sherief-abd-elsalam","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}